Topic Highlight
Copyright ©2010 Baishideng. All rights reserved
World J Gastroenterol. Aug 14, 2010; 16(30): 3773-3779
Published online Aug 14, 2010. doi: 10.3748/wjg.v16.i30.3773
Effect of medical and surgical treatment of Barrett’s metaplasia
Eelco B Wassenaar, Brant K Oelschlager
Eelco B Wassenaar, Brant K Oelschlager, Center for Videoendoscopic Surgery, Department of Surgery, University of Washington, Seattle, WA 98195, United States
Author contributions: Both authors contributed equally to the design, research and writing of the manuscript.
Correspondence to: Brant K Oelschlager, MD, Professor, Center for Videoendoscopic Surgery, Department of Surgery, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, United States. brant@uw.edu
Telephone: +1-206-6161711 Fax: +1-206-5438136
Received: April 24, 2010
Revised: June 7, 2010
Accepted: June 14, 2010
Published online: August 14, 2010
Abstract

Barrett’s esophagus (BE) is a change in the esophageal mucosa as a result of long-standing gastroesophageal reflux disease. The importance of BE is that it is the main risk factor for the development of esophageal adenocarcinoma, whose incidence is currently growing faster than any other cancer in the Western world. The aim of this review was to compare the common treatment modalities of BE, with the focus on proton pump inhibitors and operative fundoplication. We performed a literature search on medical and surgical treatment of BE to determine eligible studies for this review. Studies on medical and surgical treatment of BE are discussed with regard to treatment effect on progression and regression of disease. Although there is some evidence for control of reflux with either medical or surgical therapy, there is no definitive evidence that either treatment modality decreases the risk of progression to dysplasia or cancer. Even though there is a trend toward antireflux surgery being superior, there are no definitive studies to prove this.

Keywords: Barrett’s esophagus; Intestinal metaplasia; Proton pump inhibitors; Nissen fundoplication; Esophageal adenocarcinoma; Gastroesophageal reflux